[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"a6aa62c9-583b-4803-a3ef-71521e4f7978","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390427","created_at":"2021-01-18T11:23:47.971Z","updated_at":"2025-02-25T14:00:36.998Z","phase":"Phase 1","brief_title":"Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer","source_id_and_acronym":"NCT02390427","lead_sponsor":"Otto Metzger, MD","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • taselisib (GDC-0032)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 04/20/2015","start_date":" 04/20/2015","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-10-02"},{"id":"923e4567-18b4-42c0-a8ba-c85f2c104921","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439175","created_at":"2021-01-18T21:22:07.060Z","updated_at":"2024-07-02T16:35:05.086Z","phase":"Phase 2","brief_title":"Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)","source_id_and_acronym":"NCT04439175","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e taselisib (GDC-0032)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 11/10/2020","primary_completion_date":" 11/10/2020","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-05-08"},{"id":"31d6ffe2-4ba8-4867-90e7-d162923e570c","acronym":"Lung-MAP","url":"https://clinicaltrials.gov/study/NCT02154490","created_at":"2021-01-18T06:59:07.141Z","updated_at":"2024-07-02T16:35:46.669Z","phase":"","brief_title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","source_id_and_acronym":"NCT02154490 - Lung-MAP","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • ALK • EML4 • TP63","pipe":" | ","alterations":" EGFR mutation • ALK fusion • TTF1 negative","tags":["EGFR • ALK • EML4 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • TTF1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Talzenna (talazoparib) • Imjudo (tremelimumab-actl) • fexagratinib (ABSK091) • taselisib (GDC-0032) • rilotumumab (AMG 102)"],"overall_status":"Completed","enrollment":" Enrollment 1864","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 04/15/2022","study_completion_date":" 04/15/2022","last_update_posted":"2023-06-01"},{"id":"13c74024-07c0-46e3-ac35-99b25657ff2a","acronym":"Poseidon","url":"https://clinicaltrials.gov/study/NCT02285179","created_at":"2021-01-18T10:46:01.683Z","updated_at":"2024-07-02T16:36:02.573Z","phase":"Phase 2","brief_title":"Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen","source_id_and_acronym":"NCT02285179 - Poseidon","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • taselisib (GDC-0032)"],"overall_status":"Completed","enrollment":" Enrollment 189","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 05/01/2022","study_completion_date":" 05/01/2022","last_update_posted":"2022-10-12"},{"id":"d02a198a-9348-45d3-96bd-da2a587eb9c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01296555","created_at":"2021-01-17T17:54:30.587Z","updated_at":"2024-07-02T16:36:24.823Z","phase":"Phase 1/2","brief_title":"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT01296555","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • taselisib (GDC-0032)"],"overall_status":"Completed","enrollment":" Enrollment 686","initiation":"Initiation: 03/16/2011","start_date":" 03/16/2011","primary_txt":" Primary completion: 06/25/2021","primary_completion_date":" 06/25/2021","study_txt":" Completion: 06/25/2021","study_completion_date":" 06/25/2021","last_update_posted":"2021-09-05"},{"id":"e06d125e-be2f-4bab-b3eb-1d429ac20566","acronym":"PIPA","url":"https://clinicaltrials.gov/study/NCT02389842","created_at":"2021-01-18T11:23:37.294Z","updated_at":"2024-07-02T16:36:53.435Z","phase":"Phase 1","brief_title":"PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib","source_id_and_acronym":"NCT02389842 - PIPA","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • KRAS • PIK3CA","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation","tags":["HER-2 • KRAS • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • pictilisib (GDC-0941) • taselisib (GDC-0032)"],"overall_status":"Unknown status","enrollment":" Enrollment 93","initiation":"Initiation: 03/25/2015","start_date":" 03/25/2015","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2019-11-19"},{"id":"4513a8c1-94ac-4f9c-bf9b-a1b2792ab066","acronym":"LORELEI","url":"https://clinicaltrials.gov/study/NCT02273973","created_at":"2021-01-18T10:42:00.009Z","updated_at":"2024-07-02T16:37:10.619Z","phase":"Phase 2","brief_title":"A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)","source_id_and_acronym":"NCT02273973 - LORELEI","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • PIK3CA wild-type","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • taselisib (GDC-0032)"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 11/12/2014","start_date":" 11/12/2014","primary_txt":" Primary completion: 03/13/2017","primary_completion_date":" 03/13/2017","study_txt":" Completion: 03/13/2017","study_completion_date":" 03/13/2017","last_update_posted":"2018-05-21"},{"id":"f82fb036-bc22-485f-8ae0-57bd7ebe2d43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01862081","created_at":"2021-01-18T08:19:38.134Z","updated_at":"2024-07-02T16:37:16.021Z","phase":"Phase 1","brief_title":"A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01862081","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • taselisib (GDC-0032)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 07/16/2013","start_date":" 07/16/2013","primary_txt":" Primary completion: 06/09/2017","primary_completion_date":" 06/09/2017","study_txt":" Completion: 06/09/2017","study_completion_date":" 06/09/2017","last_update_posted":"2017-11-28"}]